COSMO PHARMACEUTICALS N.V.

Analyst Reco. Cosmo Pharmaceuticals N.V.

Equities

COPN

NL0011832936

Real-time Estimate Cboe Europe Other stock markets 07:05:00 2024-04-23 am EDT			5-day change	1st Jan Change
73.85 ^CHF	+0.61%		+4.96%	+45.38%

Mar. 20	Transcript : Cosmo Pharmaceuticals N.V. - Analyst/Investor Day
Mar. 20	Cosmo Pharmaceuticals N.V. Proposes Dividend Payment for 2024	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Berenberg Lifts Price Target on Cosmo Pharmaceuticals, Maintains Buy Recommendation	Jan. 03	MT
Berenberg EU Opportunities Conference	23-03-12	FA
Cosmo Pharmaceuticals Partner Medtronic Says GI Genius Endoscopy Lowers Colorectal Polyps Miss Rate	22-03-18	MT
Cosmo Pharmaceuticals' GI Genius Device Cuts Adenoma, Polyp Miss Rate in Colonoscopy	21-11-19	MT
Cosmo Pharmaceuticals N.V. Detects Study Shows AI Assistance Using GI Genius? Reduces Missed Polyp Rate by Nearly 50% on Initial Colonoscopy	21-11-19	CI
COSMO PHARMACEUTICALS N : Research Partners Lowers Price Target on Cosmo Pharmaceuticals, Maintains Buy Recommendation	21-03-29	MT
COSMO PHARMACEUTICALS N : Research Partners Lifts Price Target on Cosmo Pharmaceutical, Maintains Buy Recommendation	21-01-12	MT
Berenberg European Conference	18-12-04	FA
Berenberg USA Conference	18-05-21	FA
Berenberg European Conference	17-05-23	FA

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019

Replicate our performance

fermer